Clinical Trial Applications in Canada, and Comparison to the US and Europe
Overview:
This topic will cover the regulatory submission required in Canada (Clinical Trial Application) and comparison to Clinical Trial Applications in Europe and Investigational New Drug Submissions in the EU. Also covered will be the submission of documentation to Institutional Review Boards, the membership of these boards, and common findings of deficiencies for such Boards. Again, a comparison will be made to the US and EU.
The session will speak to documentation that is required for the investigator and site for Canada, and compare this to the other two jurisdictions. It will include a discussion of disbarred investigators in the US. Good Clinical Practice Regulations will be covered in the three jurisdictions, and a discussion of how ICH is recognized in terms of GCP. Also covered will be the submission of SUSARS for clinical trials and how this is done in the three jurisdictions. Finally, changes to protocols and investigational clinical trial supplies will be discussed.
Why Should You Attend :Multinational trials require different regulatory approaches to trial approval from agencies, to trial approval from Institutional Review Boards and to certifications from investigators. Learn how Canada handles Clinical Trial Applications, what regulations say about Good Clinical Practice and how Health Canada inspects clinical trials for compliance with regulations.
This session will compare requirements in Canada to those in the US and Europe so that those conducting clinical trials in these jurisdictions understand the different requirements in different countries. Institutional Review Boards or Ethics Review Committees also have different rules and varying requirements for how these Boards are informed of clinical trials. The session will also review the requirements in each of these jurisdictions for publication of information regarding the clinical trial on various registries.
Areas Covered in the Session
- Submission of CTAs/INDs
- Submission to IRBs
- Good Clinical Practice
- Suspected Unexpected Serious Adverse Drug Reactions
- Changes to Protocols
- Changes to Clinical Trial Supplies
- Publication of data on clinical trial registries
Who Will Benefit:
- Regulatory Affairs Directors/Managers/Coordinators/Associates
- Clinical Trial Managers/Coordinators
- Research and Development Managers/Directors
- Investigators
- Institutional Review Board members